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Systematic Review 
Abstract 
Introduction: NAFLD is a common cause of chronic liver disease worldwide. Progression of 
chronic liver disease leads to liver transplant, so theearly detection of the primary stages is of utmost 
importance. This study aims to perform a systematic review of pertinent literature to determine early 
stages of NASH and explorediagnostic biomarkers of ck-18 family.  
Method: This study is systematic and Meta analysis. We searched articles of different levels 
published in pub med, Cochrane collaboration library until December 9, 2016. Two independent 
reviewers assessed articles according to predefined criteria and extracted relevant data. AUC and 
values related to each biomarker in NASH, NO NAFLD and NAFLD groups were analyzed. 
Results:The total population of five studies incorporated in the meta-analysis consisted of 345 
subjects with an average age of 69.45 ± 8.40 years. The AUC related to M30 for diagnosis of NASH 
was reported between 0.60 and 0.88, which was suitable to differentiate NASH from simple 
steatohepatotitis.  
Conclusion: The results showed that M30 was a suitable biomarker for the diagnosis of 
NASH. It is considering that the use of biomarkers can reduce the need for biopsy for the diagnosis 
of NASH and consequently decreaserelated costs and risks. 
Keywords: Non-alcoholic Fatty Liver Disease, biomarkers, Nonalcoholic Steatohepatitis, NAFLD, 
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Introduction: 
Non-alcoholic fatty liver disease (NAFLD),a 
hepatic manifestation of metabolic syndrome, is 
the most common cause of chronic liver disease 
across the world (1). It is estimated that about 
30% of the adult population and less than 10% of 
children in the West suffer from NAFLD (2). 
Accordingly, 20-25% of people with NAFLD are 
prone to NASH (3). Patients with NASH have 
increased morbidity and mortality from 
cardiovascular disease, cancer and liver-related 
diseases in the total population (4). 
As we know, NAFLD includes a range of simple 
steatosis and non-alcoholic steatohepatitis (5-
6).There are increasing evidences over the past 
decade that show patients with NASH follows a 
progressive course (7). Although several 
biomarkers have been developed for NASH and 
hepatic fibrosis (8-15), biopsy is considered as an 
"imperfect gold standard" for diagnosis of NASH 
and staging of fibrosis area. In addition to being 
costly, liver biopsy depends on the sample size 
and incomplete sampling error may be resulted 
along certain risks (16-18). As a result, the 
development and discovery of non-invasive 
diagnostic biomarkers for diagnosis of NASH and 
its associated fibrosis is of paramount importance 
inclinical practices (7-21).  
Thus, to optimize outcomes of patients with liver 
disease, physicians and researchers need to 
performsuitable noninvasive tests for lasting 
detectionof subclinical liver damage and 
monitoring liver damage progress and regression. 
Recent evidences suggest that NASH 
pathogenesis includesderegulation cytokines, 
adipokines, insulin resistance and apoptosis 
markers. (22-24) On the other hand,fibrosis 
development isassociated with collagen deposition 
and other fibrogenic pathway. The two pathways 
may have common components, but they are 
distinct Thus, it may be difficult to develop a test 
for the diagnosis of NASH and staging of fibrosis. 
(24)  
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This study offers a systematic review to introduce 
biomarkers that are activated during apoptosis. 
 
Method: 
Studies Selection: 
The title and abstract of allarticles and citations 
were studied by two independent researchers (a 
pathologist and an MS in Medical Education) and 
related articles were extracted. All disagreements 
were resolved by discussion. 
Inclusion criteria: 
All studies discussing diagnostic biomarkers for 
NASH were reviewed and included in the study.  
Abstractspresented at conferences, which were 
published in journals but their full text was not 
accessible, were also included in the study. All 
articles in which the study population included of 
hepatitis B, hepatitis C and autoimmune liver 
disease and studies with an animal model were not 
included.  
Sources and search strategies: 
We searched all English articles in pubmed and 
Cochrane collaboration library databases until 
December 9, 2016. The references of articles were 
reviewed manually. The search strategy is shown 
in the following figure 1  
Key words were used" Biomarkers", "NASH', 
"Non-alcoholic Fatty Liver Disease", " 
Nonalcoholic Steatohepatitis" , " NAFLD". 
"Biomarkers” [title] AND Non-alcoholic Fatty 
Liver Disease"  [title] , “Non-alcoholic Fatty Liver 
Disease"” [title] AND Biomarkers , “Nonalcoholic 
Steatohepatitis” [title] AND Biomarkers [title], 
“Nonalcoholic Steatohepatitis”in title, abstract, 
keywords and Biomarker, “Nonalcoholic 
Steatohepatitis” in title, abstract, keywords , “Non-
alcoholic Fatty Liver Disease” in title, abstract, 
keywords and Biomarker, “NAFLD” in title, 
abstract, keywords and Biomarker, “NASH” in 
title, abstract, keywords and Biomarker. 
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Data extraction: 
In this study, patients with NASH, i.e. patients 
with steatosis, lobular inflammation, ballooning 
degeneration with and without Mallory- Denk 
bodies and /or fibrosis and patients with NAFLD, 
i.e. patients with simple steatohepatitis and the 
group with normal biopsy results were enrolled. 
Data 1- M30: the total level of CK-18 (M30 
antigen released in the process of the caspase 
cleavage neoepitope and reflecting apoptosis) 
2- M65: the total released amount of CK-18 (M65 
antigen released from all dying cells and reflecting 
total cell death including both apoptosis and 
necrosis) 
3- M30-M65: necrosis-reflecting parameter 
calculated as M65-M30 
Quality assessment 
For each article, the inclusion criteria were 
examined by two researchers based on Cochrane 
collaboration's risk of bias tool for studies 
incorporated in the meta-analysis (25). Two 
researchers evaluated the studies independently 
and differences were resolved through discussion. 
(Table 1) 
Table 1. Risk of bias for studied included in the meta-analysis  
 
Free of se-
lective 
Reporting 
Incomplete 
outcome 
data ad-
dressed 
Blinding Adequate al-
location con-
cealment 
Adequate 
sequence 
generation 
study 
Low Low Low Low Low M.Younosis, 
Low Low Low Low Low M.Younossi, 
Low Low Low Low Low L.Diab, 2008 
Low Low Low Low Low Yilmaz, 2012
(28) 
Low Low Low Low Low Kamada, 2013
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Data analysis: 
All values of biomarkers were analyzed using the 
comprehensive meta-analysis software. Results of 
biomarkers in both groups including the values or 
ratios were estimated at 95% confidence interval. 
Mean and standard deviation were calculated and 
demographic information was also reported. 
Results: 
48 studies were evaluated out of which a total of 
11 studies that met the objectives of the study 
were extracted. Of these articles, 5 were included 
in the meta-analysis for the analysis of M30 
marker values and 6 other studies introduced 
related markers for the diagnosis of NASH. A 
consistency of 98.5% was reported between the 
two reviewers.  
Specifications of studies and subjects under 
study: 
In Table 2, details of 5 studies included in the 
meta-analysis are presented. The total population 
of these 5 studies consisted of 345 patients with 
NAFLD with an average age of 45.69 ± 8.40 
years. More than 59% of subjects were female 
with an average BMI of 37.80 ± 5.8. M30 values 
were calculated for all studies and specificity and 
sensitivity was estimated based on the results of 
liver biopsy. In some studies, values of M65 and 
M65-M30 were also reported. The highest AUC 
(Area under curve) for the diagnosis of NASH 
(i.e. 0.88).was reported in the study of  L.Diab in 
2008 
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Data analysis: 
All values of biomarkers were analyzed using the 
comprehensive meta-analysis software. Results of 
biomarkers in both groups including the values or 
ratios were estimated at 95% confidence interval. 
Mean and standard deviation were calculated and 
demographic information was also reported. 
Results: 
48 studies were evaluated out of which a total of 
11 studies that met the objectives of the study 
were extracted. Of these articles, 5 were included 
in the meta-analysis for the analysis of M30 
marker values and 6 other studies introduced 
related markers for the diagnosis of NASH. A 
consistency of 98.5% was reported between the 
two reviewers.  
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Implications 
M30 results: in five studies, the value of M30 
was measured and results were compared and 
analyzed at different cut-offs based on the results 
of liver biopsy, which served as a golden standard 
for NASH diagnosis. The sensitivity and 
specificity and their positive and negative 
predictive values are also reported in Table 2. 
M30 values in patients with NASH and NAFLD 
group were analyzed in various studies, as shown 
in Figure 2. 
In the study of M.Younosis (26), AUC was 
calculated forboth M30 and M65 (with an 
estimated value of 0.814 (CI: 0.702-0.897). The 
AUC related to M30 for diagnosis of NASH was 
reported between 0.60 and 0.88, which was 
suitable to differentiate NASH from simple 
steatohepatotitis The present study also included 
an estimation of M65-M30 ratio, which was 
significantly different compared to NAFLD 
(SIMPLE STEATOHEPATITIS) and subjects 
with normal liver biopsy This study showed that a 
panel consisting of adipokines and two biological 
markers of cell death would be more fitting. 
Additionally, the value of M65 in the second 
study of M.Younosis in 2011 was higher in NASH 
group compared to no-NASH group, and this  
Figure 2. Forest plot: summary AMOUNT of M30(the total level of CK-18) IN TWO GROUP 
(NASH AND NAFLD); pooled estimates are from afixed- effects model 
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difference was statistically significant, as it was 
for M65-M30 ratio. (24) 
Other reports of biomarkers: 
In 2012, Blomme revealed that glyco marker was 
used especially in obese individualswho needed to 
be triaged for the development of steatohepatitis 
and it could differentiate NASH from 
simplesteatosis. (30) In another study in 2012, 
NASH was found to be strongly dependent on the 
level of non-HDL- c, with this value being 
significantly higher than steatosis in patients 
without lipid-lowering agents. This biomarker 
wasnot onlycost effective, but also contributed to 
the distinction of NASH from steatosis(23).Imajo 
in 2012 stated that the level of fCh in plasma was 
related to grade fibrosis and steatosis and it could 
serve as a predictor of the severity of NASH. 
Therefore, it acts as a good diagnostic marker for 
early-stage NASH in clinical practice. According 
tothese studies, AUC for the diagnosis of NASH 
with fChand fibrosis staging is 0.811 and 0.816 
respectively. In patients with simple 
steatohepatitis, the fCh level increases. (32) It has 
been shown that theserum level of ferritin in 
NASH patients is significantly higher than 
patients with simple steatohepatotitis with a cut-
off value of196 ng /ml and optimal sensitivity 
(64.2%), specificity (76.5%), PPV (88.19%) and 
NPV (43.1%) (33). In a paper by Feldstein, CK-18 
fragmente was introduced as an independent 
predictor of NASH after adjusting fibrosis, ALT, 
AST, age and length of biopsy. The estimated 
AUC for the diagnosis of NASH was0.83. (34) 
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Discussion 
As we know, nonalcoholic fatty liver disease is 
the most common chronic liver disease, which 
includes a wide range of illnesses associated with 
excessive accumulation of fat in the liver of 
people without alcohol abuse. It ranges from 
simple steatosis to steatohepatitisin terms of 
severity and can eventually lead to cirrhosis and 
hepatocellular carcinoma. (35) It has been 
reported that 14 to 30% of people in Western 
societies suffer from NAFLD (36). Obesity is 
strongly connected with NAFLD and it is a 
predictive of advanced stages of the disease. In 
light of the increasing prevalence of obesity in 
Iran and the world, this disease is expected to rise 
dramatically. (37) Therefore, the introduction of 
non-invasive diagnostic method can be helpful in 
the early stages during the process of clinical 
performance .In studies analyzed in this paper, it 
was shown that ck-18 (Cytokeratin18) was an 
epithelial cytoskeleton protein, which was 
released into the bloodstream when liver cells 
died. CK-18 is a substrate ofcaspases that are 
activated during apoptosis. Segments of CK-18 
(fragmented ck-18) are accumulated in apoptosis 
cells and then released into the bloodstream. Many 
liver damages are associated with increased 
hepatocyte apoptosis.  
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An ELISA test for the detection of caspase-
cleaved ck-18 was developed by M30, which 
producedan antibody that recognized a specific 
epitope. One of the restrictions related to the 
application of M30 is its lack of reliability in 
differentiating different patients with significant 
hepatic fat from those with steatosis and it cannot 
be used for staging fibrosis. (38) However, the 
meta-analysis in this study showed a significant 
difference in values of M30 between two groups 
of NASH and simple steatohepatitis. (P = 0.0001) 
Studies have shown that total ck-18 is a suitable 
biomarker of liver fibrosis. Although cleaved-ck-
18 level is dependent on the stage of fibrosis and 
liver stiffness, there is a strong correlation 
between liver fibrosis and total ck-18 (especially 
M65). It has been posited that total ck-18 is a 
good indicator of NAFLD / NASH compared to 
cleaved ck-18. The total ck-18 is used to evaluate 
differentiate patients based on minimal steatosis 
(hepatic fat accumulation <10%) from steatosis 
(hepatic fat> 10%). Therefore, total ck-18 is better 
at differentiating NAFLD/NASH compared to 
M30 (39). Given that pathogenesis of NASH has 
its own complexities, it is possible that cytokines 
and adipokines pathways also contribute to the 
progression of NASH. (40) Therefore, a set of 
biomarkers that containboth apoptosis markers 
and adipocytokine pathways could be used for 
differential diagnosis of NASH. 
Lack of RCT articles was Limitation of this study.  
It is recommended to perform clinical trials to 
determine characteristics of cell death biomarkers 
for the early detection of NASHFH with enhanced 
matching and precise classification. 
Conclusion:  
The results showed that M30 was a suitable 
biomarker for the diagnosis of NASH. It is 
considering that the use of biomarkers can reduce 
the need for biopsy for the diagnosis of NASH 
and consequently decrease related costs and risks.  
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